



INNOVATION | QUALITY | CARE

Date: April 30th, 2026

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001
Scrip Code: 544578

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: RUBICON

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') – Completion of Acquisition of securities in Arinna Lifesciences Limited

Dear Sir/Madam,

In continuation of our intimation dated April 15, 2026, we wish to inform you that the Company has completed the secondary acquisition of 85% stake in Arinna Lifesciences Limited today, April 30 2026, in accordance with the terms agreed under the Share Purchase Agreement.

Following the completion of the acquisition, Arinna Lifesciences Limited becomes a subsidiary of the Company.

You are requested to take the above information on record.

Yours faithfully,
For Rubicon Research Limited
(Formerly known as Rubicon Research Private Limited)

Deepashree Tanksale
Company Secretary
M. No. A28132

Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744

Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India

+91-22-61414000 / 50414000 | reachus@rubicon.co.in | www.rubicon.co.in